摘要
目的探索浙麦冬的道地性与等级评价标准。方法采集来自浙江省慈溪市与浙江省三门县的共42批浙麦冬样品,根据其每50 g粒数,将样品划分3个等级。采用HPLC对浙麦冬中7种成分的含量进行测定,并通过主成分分析综合得分评价药材的道地性。通过偏最小二乘-判别(PLS-DA)结合外观与内在化学成分含量指标对划分的等级进行判别分析。结果主成分综合得分显示来自慈溪的样品总体综合得分排名优于三门地区的样品。PLS-DA分析结果显示,42批样品可明显区分为三类,其中一等品明显聚为一类,来自浙江省慈溪市的二等品与三等品可聚为一类,来自浙江省三门县的二等品、三等品聚为一类。结合外观、内在指标共5个指标可作为分类标志物。结论传统的等级评价方法具有一定的局限性,而结合传统外观指标与内在含量指标对浙麦冬进行等级评价,结果具有一定的科学性,可为浙麦冬的等级评价提供新的思路。
OBJECTIVE To explore the geoherbalism and grand evaluation of Zhejiang Ophiopogon japonicas. METHODS A total of 42 batches of Zhejiang Ophiopogon japonicas samples were collected from Cixi city and Sanmen county, Zhejiang province. The samples were divided into three grades according to the number of grains per 50 g. HPLC method was used to determine the contents of seven components in Zhejiang Ophiopogon japonicas and evaluate the geoherbalism of samples according to the PCA synthesis score. PLS-DA was used to analyze the classification by combining appearance and intrinsic chemical content. RESULTS The result of PCA(principal component analysis) synthesis score showed that the samples from Cixi city was better than the samples from Sanmen city. The PLS-DA results showed that 42 batches of samples could be clearly divided into three categories, among which the first-class samples were obviously clustered into one category, the second-class and third-class samples from Cixi city were clustered into one category, and the second-class and third-class samples from Sanmen county were clustered into one category. Combined with appearance and internal indicators, there are five indicators that can be used as classification markers. CONCLUSION The traditional grading evaluation method has some limitations. Evaluation of the rank of Zhejiang Ophiopogon japonicus by combining the traditional appearance index and internal content index can get scientific result, which provides a new idea for the rank evaluation of Zhejiang Ophiopogon japonicas.
作者
何佳
黄文康
马相锋
马临科
吴俊
叶丽华
陈碧莲
刘雳
张文婷
HE Jia;HUANG Wen-kang;MA Xiang-feng;MA Lin-ke;WU Jun;YE Li-hua;CHEN Bi-lian;LIU Li;ZHANG Wen-ting(College of Pharmaceutical Sciences,Zhejiang Chinese Medical University,Hangzhou 310053,China;Zhejiang Institute for Food and Drug Control,Hangzhou 310052,China;State Drug Administration Key Laboratory for Quality Evaluation of Proprietary Chinese Medicines,Hangzhou 310052,China;Zhejiang Academy of Medical Sciences,Hangzhou 310015,China;Zhengda Qingchunbao Pharmaceutical Limited Company,Hangzhou 310023,China)
出处
《中国药学杂志》
CAS
CSCD
北大核心
2021年第4期285-292,共8页
Chinese Pharmaceutical Journal
基金
国家中医药管理局支撑计划资助(ZYBZH-C-ZJ-60)。